Please login to the form below

Not currently logged in
Email:
Password:

Orphan drug firm Sobi opens new European base

Company'sBrussels office will also house its Benelux operations

Swedish Orphan Biovitrum Sobi

Sobi (Swedish Orphan Biovitrum) has opened doors on its new European and Benelux office in Brussels.

The company said the move was a reflection of its expanding international presence and would act as an operational hub for its business.

Hege Hellstrom, president EMENAR at Sobi, said: "Brussels provides an ideal location for our European operations. Being a company dedicated to rare diseases, Brussels is of vital importance to Sobi from a business, regulatory, policy and stakeholder interaction perspective.

“The Belgian authorities have also consistently been thought leaders in collaborative, cross-border approaches to access and availability of rare disease therapies for patients."

The rare disease-focused specialty pharmaceutical company has more than 600 employees who concentrate primarily on its work in haemophilia, inflammation and genetic diseases.

In July the European Commission approved an oral suspension formulation of Orfadin (nitisinone), which treats the rare - and potentially fatal - genetic disease Hereditary Tyrosinaemia type-1 (HT-1).

More recently the FDA this week began its review of the oral suspension formulation of Orfadin, and Sobi said a formal decision on the product from the US regulator is expected during the second quarter 2016.

Article by
Dominic Tyer

11th September 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics